Catalyst Pharmaceuticals Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalyst Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Catalyst Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,370,000 shares, an increase of 29.5% from the March 15th total of 9,550,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the short-interest ratio is presently 7.0 days. Approximately 12.8% of the shares of the company are sold short.
View Catalyst Pharmaceuticals' Short Interest.

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Tuesday, March, 16th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The biopharmaceutical company had revenue of $31.02 million for the quarter, compared to analysts' expectations of $30.06 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.04% and a net margin of 60.48%.
View Catalyst Pharmaceuticals' earnings history.

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CPRX stock has increased by 22.4% and is now trading at $4.31.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 12-month target prices for Catalyst Pharmaceuticals' shares. Their forecasts range from $5.50 to $10.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Catalyst Pharmaceuticals include Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), Amneal Pharmaceuticals (AMRX), Cytokinetics (CYTK), Zentalis Pharmaceuticals (ZNTL), Ironwood Pharmaceuticals (IRWD), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), ADC Therapeutics (ADCT), Myovant Sciences (MYOV), Prelude Therapeutics (PRLD), uniQure (QURE), Heron Therapeutics (HRTX), Applied Molecular Transport (AMTI) and Travere Therapeutics (TVTX).
View all of CPRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.03%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals.

CPRX stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC.
View insider buying and selling activity for Catalyst Pharmaceuticals or view top insider-selling stocks.

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $4.31.

Catalyst Pharmaceuticals has a market capitalization of $447.49 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis.

Catalyst Pharmaceuticals employs 76 workers across the globe.

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]